Clinical Trials Directory

Trials / Conditions / Stage IV Rectal Cancer AJCC v8

Stage IV Rectal Cancer AJCC v8

15 registered clinical trials studyying Stage IV Rectal Cancer AJCC v8 — 2 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingFamily Communications After Genetic Testing
NCT07143487
Alliance for Clinical Trials in OncologyN/A
WithdrawnBotensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Met
NCT06575725
City of Hope Medical CenterPhase 2
WithdrawnTucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cance
NCT05356897
Academic and Community Cancer Research UnitedPhase 2
Active Not RecruitingFOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Micro
NCT05627635
City of Hope Medical CenterPhase 1 / Phase 2
Active Not RecruitingTesting the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorecta
NCT05308446
National Cancer Institute (NCI)Phase 2
Active Not RecruitingEnhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
NCT05038254
M.D. Anderson Cancer CenterN/A
Active Not RecruitingLY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastat
NCT04616183
M.D. Anderson Cancer CenterPhase 1 / Phase 2
Active Not RecruitingSX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the S
NCT04599140
M.D. Anderson Cancer CenterPhase 1 / Phase 2
CompletedRegorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metast
NCT04362839
City of Hope Medical CenterPhase 1
Active Not RecruitingPanitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type C
NCT03992456
Academic and Community Cancer Research UnitedPhase 2
TerminatedGenetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Tr
NCT03765736
Academic and Community Cancer Research United—
TerminatedSavolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
NCT03592641
National Cancer Institute (NCI)Phase 2
CompletedM7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instabil
NCT03436563
M.D. Anderson Cancer CenterPhase 1 / Phase 2
RecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
NCT02107105
M.D. Anderson Cancer Center—
Active Not RecruitingCirculating Tumor Cells in Patients With Locally Advanced Rectal Cancer
NCT02874885
M.D. Anderson Cancer Center—